Key statistics
As of last trade argenx SE (A1RG34:SAO) traded at 139.30, -1.38% below its 52-week high of 141.25, set on Nov 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 135.80 |
---|---|
High | 140.28 |
Low | 135.80 |
Bid | 139.01 |
Offer | 140.66 |
Previous close | 139.30 |
Average volume | 136.67 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Nov 22 2024 13:13 GMT.
More ▼
- argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
- argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
- argenx to Participate at Upcoming Investor Conferences
- argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
- argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
- argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
- argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
- argenx to Present at Upcoming Investor Conferences
- argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
- argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
More ▼